AZD1390, an ataxia telangiectasia mutated inhibitor, attenuates microglia-mediated neuroinflammation and ischemic brain injury.
Zhen LanLong-Jie QuYing LiangLi-Qiu ChenShuai XuJian-Wei GeZhi-Wei XueXin-Yu BaoSheng-Nan XiaHai-Yan YangJing HuangYun XuXiao-Lei ZhuPublished in: CNS neuroscience & therapeutics (2024)
AZD1390 suppressed NF-κB signaling pathway to alleviate ischemic brain injury in experimental stroke, and attenuated microglia activation and neuroinflammation, which indicated that AZD1390 might be an attractive agent for the treatment of ischemic stroke.
Keyphrases
- oxidative stress
- brain injury
- cerebral ischemia
- subarachnoid hemorrhage
- signaling pathway
- inflammatory response
- lps induced
- neuropathic pain
- atrial fibrillation
- pi k akt
- traumatic brain injury
- epithelial mesenchymal transition
- blood brain barrier
- cell proliferation
- spinal cord injury
- replacement therapy
- endoplasmic reticulum stress